Goering R V, Sanders C C, Sanders W E
Antimicrob Agents Chemother. 1982 Jun;21(6):963-7. doi: 10.1128/AAC.21.6.963.
The ability of cefoxitin to antagonize the in vivo efficacy of cefamandole and carbenicillin as predicted by in vitro assays was analyzed in experimental infections in mice. Cefoxitin was administered in a nonprotective dose either at the time of challenge or simultaneously with the protective drug, 1 and 3.5 h postchallenge. In mice infected with Enterobacter cloacae, median 50% protective doses of cefamandole and carbenicillin were markedly increased by cefoxitin, especially when the latter was given at the time of challenge. The antagonistic effect was also associated with increased numbers of challenge bacteria present in animal heart blood within a 6.5-h period after infection. In infections with Pseudomonas aeruginosa, cefoxitin antagonized carbenicillin; however, the effect was less dramatic than that seen with E. cloacae. Antagonism in this model was pronounced with simultaneous administration of antagonizing and protective drugs. The antagonistic effects observed in all in vivo tests were not due to the selection of stable resistance to the protective drugs, but appeared to be due to a reversible induction of beta-lactamases by cefoxitin.
通过体外试验预测,头孢西丁拮抗头孢孟多和羧苄西林体内疗效的能力在小鼠实验性感染中进行了分析。头孢西丁在攻击时或与保护性药物(分别在攻击后1小时和3.5小时)同时以非保护剂量给药。在感染阴沟肠杆菌的小鼠中,头孢孟多和羧苄西林的半数有效保护剂量因头孢西丁而显著增加,尤其是在攻击时给予头孢西丁时。这种拮抗作用还与感染后6.5小时内动物心血中攻击细菌数量的增加有关。在铜绿假单胞菌感染中,头孢西丁拮抗羧苄西林;然而,其作用不如在阴沟肠杆菌感染中那么显著。在该模型中,同时给予拮抗药和保护药时,拮抗作用明显。在所有体内试验中观察到的拮抗作用并非由于对保护药物产生稳定耐药性的选择,而是似乎归因于头孢西丁对β-内酰胺酶的可逆诱导。